Ian Neeland, MD, highlights that oral semaglutide is more accessible and that patients should avoid switching drug types during the shortage.
In cases where lowering the semaglutide dose is not feasible to address a drug shortage in a higher dose, an alternative for diabetes management is transitioning to oral semaglutide, which is more accessible, explains Ian Neeland, MD. Neeland serves as director of cardiovascular prevention and co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease at the University Hospitals Harrington Heart & Vascular Institute, as well as associate professor of medicine at Case Western Reserve University School of Medicine.
Transcript
In cases where you can’t lower the semaglutide dose, are there alternative treatments you recommend?
For diabetes management, someone who can't access injectable semaglutide will probably have no problem accessing oral semaglutide. Although it's difficult to understand how to transition from a high dose, let's say, to the next dose of oral, so that requires a little bit of creativity, but certainly oral semaglutide we've not seen a shortage in. So, if there's a concern over breakage in therapy [or] long-term issues with accessing medications, I'll usually use oral semaglutide for diabetes management.
[Oral semaglutide is] not labeled for obesity management, so that is an off-label method to assist with that. But usually, in regard to weight loss management, breakage in therapies are probably not as urgent in terms of that, because when patients have diabetes we want to make sure that their glycemia is controlled, whereas for weight loss, maintaining the same dose or smaller dose can still have a lot of the efficacy that you can see for weight loss. Especially people who have reached higher doses, let's say at the 2 milligram dose of semaglutide going down to the 1 milligram dose, I've found at least in my experience it's not so difficult for the patient to maintain the weight loss they have been doing, so it's not as big of an issue.
What I don't like to do, especially for weight loss or diabetes, is to switch drug types. Switching from semaglutide, for example, to tirzepatide when there's a shortage in one and not the other, I don't like that approach very much, because there's not a lot of guidance or data around the transition, the switch, at what dose to go to. So, often you have to start the lower dose even for individuals who are at much higher doses of semaglutide, and that, again, delays therapy, prolongs therapeutic escalation, and makes it more difficult. And then often there'll be a shortage in one of those medications and they'll want to switch back, so it becomes very disruptive. I try my best to maintain a certain medication—the best that's covered for them, the best they can tolerate—and just kind of go up and down on the dosages a little bit to weather that storm of drug shortage. And if I really can't get injectable in for semaglutide, I'll use the oral Rybelsus version.
This transcript has been lightly edited for clarity.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More